ArticleVaccines2020
A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity?
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- Identification of a Key Hemagglutinin Mutation Mediating Antibody Escape in Influenza A(H1N1)pdm09 Viruses.Viruses · 2026Article
- The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome.Molecules (Basel, Switzerland) · 2025Review
- Strain Variation Based on Spike Glycoprotein Gene of SARS-CoV-2 in Kuwait from 2020 to 2021.Pathogens (Basel, Switzerland) · 2022Article
- A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World.Aging and disease · 2022Article
- One-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach.Canadian geriatrics journal : CGJ · 2022Review
- Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression.The Journal of international medical research · 2022Review
- A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.Frontiers in immunology · 2022Review
- Molecular characterization of a new SARS-CoV-2 recombinant cluster XAG identified in Brazil.Frontiers in medicine · 2022Article
- The adaptation of SARS-CoV-2 to humans.Memorias do Instituto Oswaldo Cruz · 2022Article
- Article
- Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.Drug discovery today · 2021Review
- SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic Variants.Microbiology spectrum · 2021Article
- Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): Are they similar?Transboundary and emerging diseases · 2021Review
- COVIDomic: A multi-modal cloud-based platform for identification of risk factors associated with COVID-19 severity.PLoS computational biology · 2021Article
- An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.Vaccines · 2021Review
- GESS: a database of global evaluation of SARS-CoV-2/hCoV-19 sequences.Nucleic acids research · 2021Article
- Necessary problems in re-emergence of COVID-19.World journal of clinical cases · 2021Review
- Genome Sequencing Reveals a Mixed Picture of SARS-CoV-2 Variant of Concern Circulation in Eastern Uttar Pradesh, India.Frontiers in medicine · 2021Article
- Analysis of Emerging Variants in Structured Regions of the SARS-CoV-2 Genome.Evolutionary bioinformatics online · 2021Article
- Evolutionary and Antigenic Profiling of the Tendentious D614G Mutation of SARS-CoV-2 in Gujarat, India.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The S glycoprotein of coronaviruses is important for viral entry and pathogenesis with most variable sequences. Therefore, we analyzed the S gene sequences of SARS-CoV-2 to better understand the antigenicity and immunogenicity of this virus in this study. In phylogenetic analysis, two subtypes (SARS-CoV-2a and -b) were confirmed within SARS-CoV-2 strains. These two subtypes were divided by a novel synonymous mutation of D614G. This may play a crucial role in the evolution of SARS-CoV-2 to evade the host immune system. The region containing this mutation point was confirmed as a B-cell epitope located in the S1 domain, and SARS-CoV-2b strains exhibited severe reduced antigenic indexes compared to SARS-CoV-2a in this area. This may allow these two subtypes to have different antigenicity. If the two subtypes have different serological characteristics, a vaccine for both subtypes will be more effective to prevent COVID-19. Thus, further study is urgently required to confirm the antigenicity of these two subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.